Insider · CIK 0001658859
Patrick Fabbio
Files at TARA (Protara Therapeutics, Inc.), BYSI (BeyondSpring Inc.). First filing -, latest -.
In brief
Patrick Fabbio files SEC Form 4 as CFO and director at TARA (Protara Therapeutics, Inc.), and also at BYSI (BeyondSpring Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Patrick Fabbio has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | BYSI BeyondSpring Inc. | AGrant or award Stock Options (right to buy)derivative | +22,165 | $0.00 | $0 | 22,165 | Apr 3, 2026 |
| Jan 26, 2026 | TARA Protara Therapeutics, Inc. | FTax withholding Common Stock | -3,261 | $6.67 | $22k | 64,115 | Jan 27, 2026 |
| Jan 20, 2026 | TARA Protara Therapeutics, Inc. | FTax withholding Common Stock | -3,063 | $5.60 | $17k | 67,376 | Jan 22, 2026 |
| Jan 16, 2026 | TARA Protara Therapeutics, Inc. | AGrant or award Common Stock | +28,000 | $0.00 | $0 | 70,439 | Jan 21, 2026 |
| Jan 16, 2026 | TARA Protara Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +175,000 | $0.00 | $0 | 175,000 | Jan 21, 2026 |
| Apr 21, 2025 | BYSI BeyondSpring Inc. | AGrant or award Stock Options (right to buy)derivative | +23,793 | $0.00 | $0 | 23,793 | Apr 23, 2025 |
| Jan 24, 2025 | TARA Protara Therapeutics, Inc. | AGrant or award Common Stock | +23,500 | $0.00 | $0 | 45,500 | Jan 28, 2025 |
| Jan 24, 2025 | TARA Protara Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Jan 28, 2025 |
| Jan 21, 2025 | TARA Protara Therapeutics, Inc. | FTax withholding Common Stock | -3,061 | $4.76 | $15k | 18,939 | Jan 23, 2025 |
Questions about Patrick Fabbio
Answered from the filings on this page, as of the latest one.
Is Patrick Fabbio buying or selling?
Patrick Fabbio has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Patrick Fabbio's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Patrick Fabbio has 0.
Where does Patrick Fabbio file Form 4?
Patrick Fabbio has filed Form 4 at TARA (Protara Therapeutics, Inc.) as Chief Financial Officer; BYSI (BeyondSpring Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.